GoAI
Get started
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. logo

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$519

−HK$19.00 · -3.53%

Aug 24, 11:04 AM HKT

6990.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Jun You Ge
Listed since
Jul 11, 2023
Employees
2,300

Market position

Day range

Current HK$519

52-week range

Current HK$519

Open
HK$540
Previous close
HK$538
Volume
183.2K
0.2× average
Average volume
936.44K
Average daily volume
Market cap
121.03B HKD
Beta
-0.03
Market reference 1
50-day average
HK$485.05
+7.00% above average
200-day average
HK$448.44
+15.73% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
78.22B CNY
P/E (TTM)
-247.16×
P/B (TTM)
21.32×
P/S (TTM)
46.08×
EV / EBITDA
-313.85×
Earnings yield
-0.47%
Free cash flow yield
-0.38%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
71.88%
Operating margin
-16.35%
Net margin
-18.59%
Return on equity
-7.85%
Return on assets
-6.38%
Return on invested capital
-9.09%

Financial health

Debt / equity
0.02×
Current ratio
5.13×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends354%-776%-1905%-3035%Gross margin, FY2021: -34.39%Gross margin, FY2022: 65.57%Gross margin, FY2023: 49.28%Gross margin, FY2024: 65.89%Gross margin, FY2025: 71.86%Operating margin, FY2021: -2512.37%Operating margin, FY2022: -49.00%Operating margin, FY2023: -29.38%Operating margin, FY2024: -10.94%Operating margin, FY2025: -22.65%Net margin, FY2021: -2752.91%Net margin, FY2022: -76.64%Net margin, FY2023: -37.27%Net margin, FY2024: -13.80%Net margin, FY2025: -18.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -34.39%. Gross margin FY2022 65.57%. Gross margin FY2023 49.28%. Gross margin FY2024 65.89%. Gross margin FY2025 71.86%. Operating margin FY2021 -2512.37%. Operating margin FY2022 -49.00%. Operating margin FY2023 -29.38%. Operating margin FY2024 -10.94%. Operating margin FY2025 -22.65%. Net margin FY2021 -2752.91%. Net margin FY2022 -76.64%. Net margin FY2023 -37.27%. Net margin FY2024 -13.80%. Net margin FY2025 -18.56%.

Income trends

Revenue

2.06B CNY+6.46%

Operating income

−466.19M CNY-120.52%

Net income

−381.97M CNY-43.19%
Income trends across reported periods2.35B CNY1.18B CNY4.69M CNY−1.17B CNYRevenue, FY2021: 31.79M CNYRevenue, FY2022: 803.93M CNYRevenue, FY2023: 1.54B CNYRevenue, FY2024: 1.93B CNYRevenue, FY2025: 2.06B CNYOperating income, FY2021: −798.79M CNYOperating income, FY2022: −393.93M CNYOperating income, FY2023: −452.61M CNYOperating income, FY2024: −211.4M CNYOperating income, FY2025: −466.19M CNYNet income, FY2021: −875.26M CNYNet income, FY2022: −616.1M CNYNet income, FY2023: −574.13M CNYNet income, FY2024: −266.77M CNYNet income, FY2025: −381.97M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 31.79M CNY. Revenue FY2022 803.93M CNY. Revenue FY2023 1.54B CNY. Revenue FY2024 1.93B CNY. Revenue FY2025 2.06B CNY. Operating income FY2021 −798.79M CNY. Operating income FY2022 −393.93M CNY. Operating income FY2023 −452.61M CNY. Operating income FY2024 −211.4M CNY. Operating income FY2025 −466.19M CNY. Net income FY2021 −875.26M CNY. Net income FY2022 −616.1M CNY. Net income FY2023 −574.13M CNY. Net income FY2024 −266.77M CNY. Net income FY2025 −381.97M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue2.06B CNY1.93B CNY1.54B CNY803.93M CNY31.79M CNY
Cost of goods sold579.14M CNY659.39M CNY781.31M CNY276.83M CNY42.73M CNY
Gross profit1.48B CNY1.27B CNY759.19M CNY527.11M CNY−10.93M CNY
Research and development1.32B CNY1.21B CNY1.03B CNY845.98M CNY715.79M CNY
Selling, general, and administrative284.72M CNY129.23M CNY66.17M CNY22.87M CNY72.06M CNY
Operating expenses1.94B CNY1.49B CNY1.21B CNY921.03M CNY787.85M CNY
Interest income63.54M CNY34.18M CNY45.19M CNY1.42M CNY792.84K CNY
Interest expense6.16M CNY3.8M CNY84.31M CNY148.81M CNY110.75M CNY
Depreciation and amortization100.4M CNY91.39M CNY75.08M CNY67.36M CNY22.54M CNY
Operating income−466.19M CNY−211.4M CNY−452.61M CNY−393.93M CNY−798.79M CNY
Net income−381.97M CNY−266.77M CNY−574.13M CNY−616.1M CNY−875.26M CNY

Company facts updated Aug 24, 2026.

6990.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

ETFs holding 6990.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
57.26M
Weight
0.01%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
55.6M
Weight
0.03%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.45+0.72%
iShares Core MSCI Emerging Markets ETF logoiShares Core MSCI Emerging Markets ETFIEMG
Market value
40.63M
Weight
0.03%
AUM
160B USD
Expense ratio
0.09%
Price / 1D
$81.57+0.64%
Global X China Biotech ETF (HKD) logoGlobal X China Biotech ETF (HKD)2820.HK
Market value
15.35M
Weight
2.52%
AUM
709.7M HKD
Expense ratio
0.68%
Price / 1D
HK$73.46-3.97%
iShares MSCI Emerging Markets ETF logoiShares MSCI Emerging Markets ETFEEM
Market value
9.5M
Weight
0.03%
AUM
31.22B USD
Expense ratio
0.72%
Price / 1D
$67.12+0.75%
iShares MSCI China ETF logoiShares MSCI China ETFMCHI
Market value
9.18M
Weight
0.15%
AUM
6.29B USD
Expense ratio
0.59%
Price / 1D
$55.66+0.27%
Vanguard FTSE All-World ex-US ETF logoVanguard FTSE All-World ex-US ETFVEU
Market value
9.17M
Weight
0.01%
AUM
95.9B USD
Expense ratio
0.04%
Price / 1D
$85.69+0.82%
iShares ESG Aware MSCI EM ETF logoiShares ESG Aware MSCI EM ETFESGE
Market value
7.84M
Weight
0.11%
AUM
6.91B USD
Expense ratio
0.25%
Price / 1D
$53.93+0.82%

Continue in GoAI

Research 6990.HK

research.disclaimer